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Recent experimental studies have demonstrated an essential role for the Hippo-Yes-associated 
protein (YAp) pathway in GNAQ/GNA11-induced tumorigenesis in uveal melanoma (UM). However, 
the association between YAp activity and clinical outcomes remains elusive. We investigated possible 
associations between YAp activity and clinicopathological features including survival outcomes in 
patients with UM using the cancer Genome Atlas (tcGA) cohort and our local cohort. We estimated 
YAp activity by mRnA expression levels, Gene Set Variation Analysis (GSVA) for the tcGA cohort, and 
immunohistochemical YAp staining for the local cohort. in the tcGA cohort, most clinicopathological 
features including tumor stage, mitotic counts, mutation of genes, and tumor sizes did not significantly 
differ between low and high YAP activity groups. In the local cohort, YAP nuclear-positive staining was 
observed in 30 (42%) of 72 patients with primary UM. UM-specific survival was not significantly different 
between tumors with low and high YAp activities. Unlike mesothelioma cells harboring a mutation of 
negative regulators of YAP, the survival of multiple UM cell lines was not significantly reduced by YAP/
TAZ depletion. Our results suggest that the effect of YAP on development, growth, and invasion of UM 
in actual patients is less than previously demonstrated in experimental studies.
Uveal melanoma (UM) is the most common primary intraocular tumor of the adult population, comprising 
approximately 5% of all melanomas1,2. Primary UM responds favorably to radiotherapy, with a local recurrence 
rate of approximately 5%1. However, systemic metastasis occurs in up to 50% of patients with UM, even after enu-
cleation, and there is currently no effective treatment option for UM metastasis3. Despite advances in chemother-
apy including targeted therapy and immunotherapy, the therapeutic outcome of metastatic UM has not essentially 
improved4,5.
The introduction of next generation sequencing (NGS) has recently identified many genes, prognostic factors, 
and therapeutic targets associated with human cancers6. There have also been intense research efforts to develop 
effective drugs for UM using the results of NGS7,8. Most UM tumors harbor the GNAQ or GNA11 mutations; 
these mutants have been shown to activate oncogenic pathways, including the mitogen-activated protein kinase 
(MAPK) and Hippo-Yes-associated protein (YAP) pathways9–11. Based on these studies, phase II/III clinical trials 
using the MEK1/2 inhibitor, selumetinib, have been conducted, but selumetinib monotherapy or combination 
therapy with dacarbazine has failed to increase the overall survival of patients with UM12,13.
Recent studies have reported that the Hippo-YAP pathway is important for cancer cell proliferation and main-
tenance of cancer stem cell-like properties in many human cancers14,15. In addition, hyperactive YAP is known 
to be important for metastasis or the acquisition of resistance to anticancer agents16–19. YAP mRNA expres-
sion levels and YAP-regulated molecular signatures have been shown to be prognostic factors in the survival of 
patients with pancreatic ductal adenocarcinoma and those with oral squamous cell carcinoma, respectively20–22. 
Immunohistochemical nuclear YAP staining has also been reported as a significant prognostic factor in ade-
nocarcinomas of the ampulla of Vater23. In vitro studies and xenograft models have demonstrated an essential 
role for the Hippo-YAP pathway in GNAQ- and GNA11-induced tumorigenesis, and have suggested that YAP 
is a potential drug target for UM10,11,24. However, the results of basic and translational studies have not been 
validated in patients with UM and multiple UM cell lines. In this study, we investigated the association between 
YAP activity and clinicopathological characteristics in patients with UM using two clinical cohorts, The Cancer 
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Genome Atlas (TCGA) cohort and a local cohort with resected tumor tissues. We also investigated the effect of 
YAP/Transcriptional coactivator with PDZ-binding motif (TAZ) depletion on survival of multiple UM cell lines.
Results
Study population. For the TCGA cohort, all patients had UM with choroid or ciliary body involve-
ment. Among them, two patients had UM involving the choroid, ciliary body, and iris. The mean RNA-seq by 
Expectation Maximization (RSEM)-normalized YAP mRNA levels were 1430.5 ± 362.4 and 2719.4 ± 700.8 for 
the low expression and high expression groups, respectively (P < 0.001). The mean Gene Set Variant Analysis 
(GSVA) scores for the YAP signature were 0.162 ± 0.115 and 0.168 ± 0.124 in the low YAP signature and high 
YAP signature groups, respectively (P < 0.001; Fig. 1a). When compared with the YAP-downregulated group, the 
YAP signature gene sets were significantly upregulated in the high YAP signature group (normalized enrichment 
score: 2.30; P < 0.001; Fig. 1b and Supplementary Fig. 1). The clinicopathological characteristics of the TCGA 
cohort are listed in Table 1.
Regarding the local cohort, from January 2001 to December 2012, surgical resections of primary UM were 
performed in 74 patients; the resulting formaldehyde-fixed and paraffin-embedded tissues were available from 72 
patients. Among these 72 patients, 61 and 11 were treated with enucleation and sclerouvectomy with brachyther-
apy, respectively. When immunohistochemical (IHC) staining for YAP was performed on these tissues, YAP 
nuclear-negative staining was observed in 42 patients, whereas YAP nuclear-positive staining was observed in 30 
patients (Fig. 1c,d). The mean ages were 51.3 ± 14.6 and 53.6 ± 16.1 years in the YAP nuclear-negative and YAP 
nuclear-positive groups, respectively (P = 0.53). Twenty-four and 14 patients in the YAP nuclear-negative and 
YAP nuclear-positive groups, respectively, were male (P = 0.47).
Largest basal diameter and thickness of tumors. In the TCGA cohort, based on the YAP mRNA 
expression levels, the largest basal diameters and thicknesses were not significantly different between the YAP 
Figure 1. Estimated YAP activity based on Gene Set Variant Analysis of mRNA-seq data in the TCGA cohort, 
and immunohistochemical YAP staining in the local cohort. (a) Gene Set Variant Analysis Score for the YAP 
signature. (b) Gene Set Enrichment Analysis comparing low and high YAP signature groups. (c) Representative 
image of a YAP nuclear-negative tumor. (d) Representative image of a YAP nuclear-positive tumor.
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mRNA low expression and high expression groups (P = 0.70 and P = 0.72, respectively; Fig. 2a,b and Table 1). 
When comparing the lower 25% and upper 25%, the largest tumor basal diameters and thicknesses also did 
not significantly differ (P = 0.36 and P = 0.74, respectively). When comparing the low YAP signature and high 
YAP signature groups, there were no significant differences in tumor basal diameter and thickness (P = 0.13 and 
P = 0.79, respectively; Fig. 2c,d and Table 1). No significant differences were observed in tumor diameter and 
thickness between the lower 25% and upper 25% of the GSVA scores for the YAP signature (P = 0.16 and P = 0.49, 
respectively).
In the TCGA cohort, the largest basal diameter and thickness were significantly correlated (P < 0.001; 
R2 = 0.205). However, the YAP mRNA levels were not associated with tumor diameter or thickness (P = 0.14 or 
P = 0.18, respectively; R2 = 0.028 or R2 = 0.023, respectively; Supplementary Fig. 2a,b). GSVA scores were also not 
correlated with tumor diameter or thickness (P = 0.06 or P = 0.42, respectively; R2 = 0.044 or R2 = 0.008, respec-
tively; Supplementary Fig. 2c,d).
In the local cohort, when the YAP nuclear-negative and YAP nuclear-positive groups were compared, the larg-
est basal diameter was significantly smaller in the YAP nuclear-positive group (12.5 ± 2.9 mm vs. 10.9 ± 3.2 mm; 
P = 0.038; Fig. 2e), whereas the tumor thicknesses were not significantly different between groups (9.5 ± 0.6 mm 
vs. 9.7 ± 0.5 mm; P = 0.81; Fig. 2f).
UM-specific survival. UM-specific survival was not significantly different between the low expression and 
high expression groups [hazard ratio (HR): 1.173; 95% confidential interval (CI): 0.483–2.850; P = 0.72; Fig. 3a]. 
UM-specific survival also did not differ between the low YAP signature and high YAP signature groups (HR: 
1.272; 95% CI: 0.523–3.093; P = 0.62; Fig. 3b). Tumors that exhibited YAP nuclear-positive staining were not 
associated with poor UM-specific survival (HR: 0.786; 95% CI: 0.369–1.675; P = 0.53; Fig. 3c).
Metastasis. In the local cohort, 19/42 (45%) and 19/30 (63%) patients developed metastases in the YAP 
nuclear-negative and YAP nuclear-positive groups, respectively. Liver metastasis was observed in 17 and 18 
patients in the YAP nuclear-negative and -positive groups, respectively. Extrahepatic metastasis occurred in two 
patients in the YAP nuclear-negative group and one patient in the YAP nuclear-positive group. Details of the 
metastatic sites are listed in Supplementary Table 1.
YAP mRNA expression level
P-value











Number of Patients 40 40 — 40 40 —
Age, years, Mean (SD) 63.0 (15.0) 61.4 (13.1) 0.62 64.9 (13.2) 59.5 (14.4) 0.09
Male, No. (%) 23 (57.5%) 22 (55%) 0.99 22 (55%) 23 (57.5%) 0.99
Basal diameter (mm)* 16.3 ± 3.8 16.8 ± 3.8 0.72 15.9 ± 3.7 17.2 ± 3.9 0.13
Thickness (mm)* 10.3 ± 2.7 10.5 ± 2.9 0.7 10.3 ± 2.6 10.5 ± 3.0 0.79
AJCC stage (8th edition)
   Stage IIA, No. (%) 3 (7.5%) 1 (2.5%) 0.9 3 (7.5%) 1 (2.5%) 0.6
   Stage IIB, No. (%) 17 (42.5%) 15 (37.5%) 17 (42.5%) 15 (37.5%)
   Stage IIIA, No. (%) 12 (30%) 15 (37.5%) 10 (25%) 17 (42.5%)
   Stage IIIB, No. (%) 5 (12.5%) 5 (12.5%) 6 (15%) 4 (10%)
   Stage IIIC, No. (%) 1 (2.5%) 2 (5%) 2 (5%) 1 (2.5%)
   Stage IV, No. (%) 2 (5%) 2 (5%) 2 (5%) 2 (5%)
Dominant cell types
   Spindle, No. (%) 34 (85%) 23 (57.5%) 0.013 33 (82.5%) 24 (60%) 0.047
   Epithelioid, No. (%) 6 (15%) 17 (42.5%) 7 (17.5%) 16 (40%)
Pigmentation
   Minimal, No. (%) 14 (35%) 25 (62.5%) 0.025 19 (47.5%) 20 (50%) 0.99
   Marked, No. (%) 26 (65%) 15 (37.5%) 21 (52.5%) 20 (50%)
Mitotic count
   0-5/HPF, No. (%) 32 (80%) 31 (77.5%) 0.84 34 (85%) 29 (72.5%) 0.42
   5-10/HPF, No. (%) 6 (15%) 5 (12.5%) 4 (10%) 7 (17.5%)
   >11/HPF, No. (%) 2 (5%) 4 (10%) 2 (5%) 4 (10%)
GNAQ/11 mutation, No. (%) 37 (92.5%) 36 (90%) 0.99 38 (95%) 35 (87.5%) 0.43
BAP1 mutation, No. (%) 13 (32.5%) 22 (55%) 0.07 13 (32.5%) 22 (55%) 0.07
EIF1AX mutation, No. (%) 6 (15%) 4 (10%) 0.74 6 (15%) 4 (10%) 0.74
SF3B1 mutation, No. (%) 11 (27.5%) 7 (17.5%) 0.42 13 (32.5%) 5 (12.5%) 0.06
Table 1. Clinicopathologic characteristics of patient groups in TCGA cohort. SD = standard deviation, No. = 
Number, AJCC = American Joint Committee on Cancer. *Data are presented as mean ± standard deviation.
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comparison of iHc staining patterns between primary and metastatic UM tumors. There were 
16 metastatic UM tumors (liver metastasis); nine (56%) showed a YAP nuclear-positive pattern using IHC stain-
ing. The YAP IHC staining patterns did not significantly differ between primary (n = 72) and metastatic (n = 16) 
UM tumors (P = 0.41).
Effect of YAP knockdown on cell survival. The siRNA-mediated knockdown of YAP and its paralog, 
TAZ, significantly suppressed expression of YAP mRNA (Supplementary Fig. 3). In two mesothelioma cell lines 
[MSTO-211H (LATS2 mutation) and H2373 (NF2 mutation)] and RPE1 cells, survival was significantly reduced 
at 72 hours after YAP/TAZ siRNA transfection (Supplementary Fig. 4). In these three cell lines, reduction in cell 
survival became evident over time. At 144 hours after siRNA transfection, relative survival proportions were 
Figure 2. Comparison of tumor size according to YAP activity. (a,b) YAP mRNA low and high expression 
groups. (c,d) Low and high YAP signature groups. (e,f) YAP nuclear-negative and -positive groups. Error bars 
represent standard deviations.
Figure 3. Kaplan–Meier curves showing uveal melanoma-specific survival for low and high YAP activities. (a) 
Comparison between low and high YAP mRNA expression groups (P = 0.72). (b) Comparison between low 
and high YAP signature groups (P = 0.62). (c) Comparison between YAP nuclear-negative and -positive groups 
(P = 0.53).
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0.02 ± 0.01 (P < 0.001), 0.05 ± 0.02 (P < 0.001), and 0.28 ± 0.07 (P < 0.001) for the RPE1, MSTO-211H, and 
H2373 cells, respectively (Fig. 4).
YAP/TAZ knockdown exhibited smaller effects on survival in multiple UM cell lines (92.1, MP41, MP46, 
and MP65). Compared with RPE1, MSTO-211H, and H2373 cell lines, 92.1, MP41, MP46, and MP65 cell lines 
did not exhibit significant reduction in cell survival at 72 hours after siRNA transfection (Supplementary Fig. 4). 
Similar results were observed at 144 hours after transfection (Fig. 4). These results suggested that the effect of YAP 
on cell survival was much smaller in UM cell lines than in RPE1 cell line and mesothelioma cell lines.
Discussion
Cancer genome sequencing efforts have identified frequently mutated genes in UM, including GNAQ, GNA11, 
BAP1, SF3B1, and EIF1AX7,25. Mutations of these genes are reportedly associated with the development or prog-
nosis of UM7,26,27. Remarkably, GNAQ and GNA11 are mutated in most UM tumors (~93%) with hotspot muta-
tions (Q209P/L)7. Recent studies have highlighted the roles of GNAQ and GNA11 mutations in UM development. 
GNAQ and GNA11 mutations result in constitutive activation of oncogenic Gq/G11 subunits, leading to UM 
tumorigenesis by sequential activation of YAP10,11,23.
The Hippo-YAP signaling pathway is a key determinant of organ size, stem cell homeostasis, and cellular dif-
ferentiation14,16. Two Hippo pathway transducers, YAP and its paralog TAZ, are transcriptional coactivators with 
nuclear-cytoplasmic distributions that are mainly controlled by Hippo signaling28. LATS1/2, MST1/2, and NF2 
are the major upstream kinases of YAP, which cause YAP cytoplasmic retention and degradation by phosphoryl-
ating YAP14. Nuclear YAP (the active form of YAP) induces the expression of cell proliferative and anti-apoptotic 
genes, mainly by interacting with TEAD family transcription factors14. In experimental models using the 92.1 UM 
cell line, inhibition of YAP by short hairpin RNA or verteporfin suppressed the growth of UM10,11.
Figure 4. Effects of siRNA-mediated YAP knockdown on cellular proliferation in multiple uveal melanoma cell 
lines (92.1, MP41, MP46, and MP65) and other cell lines. Viable cells were quantified at 144 hours after siRNA 
transfection. Error bars represent standard error of the mean (n = 3 independent experiments).
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Previous studies have reported that high YAP activity is associated with poor prognoses in various cancers14,22. 
In this study, we investigated the association between YAP activity and clinicopathological characteristics using 
the TCGA cohort and a local cohort. Nucleocytoplasmic shuttling of YAP is rapidly changed by various cellular 
cues; YAP phosphorylated by Hippo kinases shows cytoplasmic retention, followed by rapid degradation by the 
proteasome15. Therefore, YAP mRNA levels may not reflect YAP activity. To overcome this limitation, we also 
estimated YAP activity by calculating the enrichment score for the YAP conserved signature genes by GSVA for 
each tumor sample. In the TCGA cohort, epithelioid cell type and marked pigmentation were associated with 
high YAP activity. However, the cancer stages, mitotic counts, and gene mutation profiles did not differ between 
groups. Consistently, the YAP mRNA expression levels and GSVA scores for YAP signatures were not significantly 
associated with tumor size and prognosis.
We further validated the clinical outcomes in the local cohort. With respect to YAP, because subcellular locali-
zation reflects activity, it is possible to estimate YAP activity by using IHC staining28. YAP nuclear staining, which 
indicated active YAP, was observed in only 30 (42%) of patients with UM; moreover, YAP IHC staining patterns 
were not significantly different between primary and metastatic tumors. Tumor size and prognosis were also not 
significantly different between the YAP nuclear-negative and YAP nuclear-positive groups.
Although YAP activities measured by several methods were not associated with the prognoses of patients with 
UM, YAP may be a therapeutic target for UM if suppression of YAP activity significantly affects the survival of 
UM cell lines. To confirm this possibility, we investigated whether siRNA-mediated YAP knockdown affected the 
survival of UM cell lines. YAP knockdown slightly reduced the survival of 92.1, MP41, MP46, and MP65 UM cell 
lines. However, these effects were much smaller than the effects observed for the two mesothelioma cell types, 
MSTO-211H (LATS2 mutation) and H2373 (NF2 mutation), which harbor mutations in negative regulators of 
YAP29. In the TCGA mesothelioma cohort, 35 (42%) of 83 patients had mutations in MST1/2, LAST1/2, or NF 
(negative upstream regulators of YAP). In another analysis, a high YAP signature was associated with poor prog-
noses in the TCGA mesothelioma cohort (HR: 2.675; 95% CI: 1.63–4.389; P < 0.001)22.
In conclusion, our results suggested that the effects of YAP on development, growth, and invasion of UM 
in affected patients were much less than the effects observed in experimental studies. However, YAP may con-
tribute to the failure of anti-cancer therapies in patients with UM. It has been shown that YAP is important for 
acquisition of resistance to targeted therapy in tumors with KRAS and BRAF mutations, and that YAP can induce 
immune evasion by increasing the expression of PD-L116–19,30. YAP activation by the GNAQ and GNA11 muta-
tions may explain the failure of MEK1/2 inhibitors or immunotherapy in patients with UM. Additional studies 
are therefore needed to determine the exact role of YAP in the treatment of UM.
Methods
the tcGA cohort and data acquisition. mRNA expression (RNA Seq V2, RSEM) data were obtained 
from the TCGA dataset for 80 patients with UM via Firebrowse (Broad Institute, Cambridge, MA, USA). RSEM 
is a tool for quantifying transcript abundances from RNA-seq data31. The TCGA provides RSEM-normalized 
data for RNA-seq; therefore, we used these data. Clinicopathological characteristics and tumor size data were 
also downloaded from Firebrowse. Updated follow-up survival data were downloaded using R package TCGA 
biolinks (http://bioconductor.org/packages/release/bioc/html/TCGAbiolinks.html).
the local cohort. This study analyzed a consecutive cohort of patients with UM who underwent surgical 
resection of primary tumors (enucleation or sclerouvectomy, 72 patients) or metastatic tumors (liver metastasis, 
16 patients) at Severance Hospital (Yonsei University College of Medicine, Seoul, Republic of Korea) between 
January 2001 and December 2012. The medical records of patients who met the following inclusion criteria were 
retrospectively reviewed: (1) pathological confirmation; (2) presence of formaldehyde-fixed, paraffin embed-
ded tissue blocks with adequate remaining tissue for additional immunohistochemical IHC staining of slides; 
and (3) available clinical follow-up data. This research adhered to the tenets of the Declaration of Helsinki. The 
Institutional Review Board/Ethics Committee approved this retrospective study (Severance Hospital, Yonsei 
University Health System, IRB no. 4-2016-0300), and informed consent for the surgical procedure was obtained 
from all participants before surgery.
Gene set enrichment analysis (GSeA) and GSVA analysis. GSEA is a popular framework for con-
densing information from gene expression profiles into a pathway or signature summary32. GSVA is a method 
that estimates variation of pathway activity over a sample population33. We used the GSEA and GSVA methods to 
estimate the YAP activity from RNA-seq data. GSVA was performed using the R package GSVA. A list of genes for 
the YAP signature was determined using MSigDB (CORDENONSI_YAP_CONSERVED_SIGNATURE, Broad 
Institute)34. The normalized count data calculated by expectation maximization analysis were incorporated as a 
matrix in R31. The enrichment score was then calculated by GSVA for each tumor sample in the matrix data using 
the following arguments: kcdf = “Poisson”, min.sz = 5, max_sz = 500, mx.diff = TRUE. GSEA was performed 
using the C6 MSigDB gene set database to test whether the YAP signature was enriched in the high YAP signature 
group, compared with the low YAP signature group32. For detailed information, see: http://software.broadinsti-
tute.org/gsea/index.jsp and Supplementary Table 2.
iHc staining for YAp. A representative area of each tumor on the formalin-fixed, paraffin-embedded block 
was punched out and a 5-mm tissue core was placed into a recipient block. Two tissue cores were extracted 
to minimize extraction bias. To generate a tissue microarray, each tissue core was assigned. Tissue microar-
ray blocks were used to obtain 5-μm-thick sections. IHC was performed with an anti-YAP antibody (dilution: 
1:200; sc-101199; Santa Cruz Biotechnology, Dallas, TX, USA) in an automated immunohistochemical stain-
ing instrument (Ventana BenchMark XT; Ventana Medical System, Oro Valley, AZ, USA), in accordance with 
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the manufacturer’s instructions. An Ultraview Universal Alkaline Phosphatase Red Detection Kit (Roche 
Diagnostics, Risch-Rotkreuz, Switzerland) was used for detection. IHC staining of all slides was interpreted by 
an expert melanoma pathologist (Sang Kyum Kim). The expression of nuclear YAP was semi-quantitatively eval-
uated by calculating the total immunostaining score (TIS), which is the product of the intensity score (IS), and 
proportion score (PS). IS represents the estimated staining intensity compared with that of control cells (0, no 
staining; 1, weak; 2, moderate; 3, strong); PS describes the estimated area of positively stained tumor cells (0, 
none; 1, <10%; 2, 10–50%; 3, 51–80%; 4, >80%). The TIS (IS × PS) ranges from 0 to 12 with only 10 possible 
values (0, 1, 2, 3, 4, 6, 7, 8, 9, and 12). The TIS was used to define the YAP nuclear-negative group (TIS 0–3) and 
YAP nuclear-positive group (TIS 4–12).
Study groups. For the TCGA cohort, patients were classified according to YAP mRNA levels and GSVA 
scores for the YAP signature as follows: (1) low expression (lower 50%, n = 40) vs. high expression (upper 
50%, n = 40) for the YAP mRNA levels; and (2) low YAP signature (lower 50%, n = 40) vs. high YAP signature 
(upper 50%, n = 40) for the GSVA scores. Based on the IHC results, patients were divided into two groups: YAP 
nuclear-negative and YAP nuclear-positive.
outcome measures. The main outcome measure was the difference in UM-specific survival between the 
two groups according to YAP activity. The other clinicopathological features included patient age, sex, American 
Joint Committee on Cancer (AJCC; 8th edition) stage, dominant cell type, pigmentation, mitotic count, largest 
tumor basal diameter, tumor thickness, presence or absence of metastasis, and metastatic sites.
In vitro cell culture and siRnA-mediated YAp knockdown. UM cells (MP41 MP46, and MP65) and 
RPE1 cells were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA)33. MSTO-
211H, H2373 and 92.1 cells were kind gifts from Joon Kim (KAIST, Daejeon, Republic of Korea)35. RPE1 cells 
were cultured in DMEM/F12 (Welgene, Kyungsan-si, Republic of Korea); other cells were cultured in RPMI-1640 
(Welgene) supplemented with 20% fetal bovine serum (Welgene) and 1% penicillin/streptomycin (Welgene). 
siRNA transfection was performed with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), in accord-
ance with the manufacturer’s reverse transfection instructions. Allstars Negative Control siRNA (Qiagen, Hilden, 
Germany) was used as a control siRNA. Published and validated sequences of siRNA for YAP/TAZ were used as 
follows: YAP1: 5′-GACAUCUUCUGGUCAGAGAdTdT-3′ and TAZ: 5′-ACGUUGACUUAGGAACUUUdTdT-
3′28. Each siRNA was used at a final concentration of 10 nM.
Quantitative Rt-pcR. Total RNA was extracted from cells using an RNeasy kit (Qiagen). A total 
of 1 μg of extracted RNA was annealed with oligo dT primer (Roche Life Science, Basel, Switzerland), 
and reverse-transcribed to cDNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA) in 
the presence of RNase Inhibitor (RNasin Plus; Promega). cDNA was mixed with primers and iQ SYBR 
Green Supermix (Bio-Rad, Hercules, CA, USA), and mRNA expression levels were measured by real-time 
qRT-PCR using a CFX96 system (Bio-Rad). qRT-PCR primers used in this study were: glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) forward: 5′-CAACGGATTTGGTCGTATTG-3′, GAPDH reverse: 
5′-GCAACAATATCCACTTTACCAGAGTTAA-3′, YAP forward: 5′-AATTTGCCCAGTTATACCTCAGTG-3′, 
and YAP reverse: 5′-CACATCAAGGCTATGATTCAAACTC-3′.
cell survival analysis. Cells were seeded on Black/Clear flat-bottomed 96-well plates (Falcon, Corning, 
NY, USA) at 3,500–5,000 cells per well for reverse transfection of siRNA. Cells were then incubated for 72 and 
144 hours; viable cells were quantified using Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, 
MD, USA).
Statistical analysis. Statistical analyses were performed using SPSS statistical software for Windows, ver-
sion 25.0 (IBM Corp., Armonk, NY, USA); Prism software, version 6 (GraphPad Software, La Jolla, CA, USA); 
or R software version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria). The chi-squared test and 
Fisher’s exact test were used to compare two groups. Pearson’s correlation coefficient was used to measure statisti-
cal relationships. The Kaplan–Meier method and log-rank test were used for comparisons of patient survival. All 
tests were two-tailed, and P < 0.05 was considered to be statistically significant.
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